electroCore

electroCore is a medical technology company developing non-invasive neuromodulation therapies. The company's flagship product, gammaCore, is a transcutaneous vagus nerve stimulation (tVNS) device approved for episodic cluster headache and being investigated for other neurological conditions including Parkinson's disease[@electrocore2024].

Company Overview

electroCore is a medical technology company developing non-invasive neuromodulation therapies. The company's flagship product, gammaCore, is a transcutaneous vagus nerve stimulation (tVNS) device approved for episodic cluster headache and being investigated for other neurological conditions including Parkinson's disease[@electrocore2024].

Company Overview

| Attribute | Value |
|-----------|-------|
| Founded | 2005 |
| Headquarters | Basking Ridge, New Jersey, USA |
| Stock | NASDAQ: ECOR |
| Focus | Non-invasive vagus nerve stimulation (tVNS) |
| Stage | Commercial + clinical development |
| Website | [electrocore.com](https://www.electrocore.com) |

Company Background

electroCore was founded to develop non-invasive neuromodulation technologies based on proprietary vagus nerve stimulation technology. The company's approach allows for transcutaneous (through the skin) stimulation of the vagus nerve, avoiding the need for surgical implantation required by traditional vagus nerve stimulation devices.

The company's name reflects its core technology—"electro" refers to electrical stimulation, and "core" represents the central role of the vagus nerve in modulating various physiological systems.

electroCore is a publicly traded company (NASDAQ: ECOR) focused on advancing tVNS therapy across multiple neurological and autonomic conditions.

Technology Platform

gammaCore Device

gammaCore is a handheld, prescription-only transcutaneous vagus nerve stimulation (tVNS) device:

• Delivery method: Non-invasive stimulation through the skin at the neck (cervical) or ear (auricular)
• Mechanism: Electrical stimulation activates vagus nerve afferent fibers, modulating brainstem and central nervous system activity
• Portable: Small, battery-operated device for home use
• Programmable: Adjustable stimulation parameters

Mechanism of Action

The gammaCore device works through several mechanisms relevant to Parkinson's disease:

Clinical Applications

Current Approvals

• Episodic cluster headache: gammaCore is FDA-cleared for the acute treatment of episodic cluster headache

Parkinson's Disease Research

electroCore is actively investigating tVNS for Parkinson's disease:

• Mechanistic rationale: Multiple studies suggest VNS may improve motor function in PD through:
• Reduction of neuroinflammation
• Modulation of basal ganglia circuitry
• Improvement of gait and postural control
• Autonomic function normalization
• Clinical evidence: Several clinical trials have explored tVNS in PD, with some showing improvements in:
• Motor scores (UPDRS)
• Gait parameters
• Postural stability
• Autonomic function
• Ongoing trials: Additional trials are evaluating tVNS as a potential treatment for PD motor symptoms and non-motor manifestations

Additional Pipeline Programs

| Indication | Development Stage | Status |
|------------|-------------------|--------|
| Episodic cluster headache | FDA-cleared | Commercial |
| Parkinson's disease | Clinical development | Investigational |
| Epilepsy | Clinical development | Investigational |
| Migraine | Clinical development | Investigational |
| Tinnitus | Clinical development | Investigational |
| Insomnia | Preclinical/Clinical | Investigational |

Competitive Landscape

electroCore operates in the non-invasive neuromodulation space:

• Non-surgical advantage: Unlike traditional VNS (Inspire/medtronic), gammaCore requires no implantation
• Portable: Can be used at home without medical supervision
• Multiple indications: Pursuing broad neurological and autonomic applications

• LivaNova (traditional VNS)
• medtronic (traditional VNS, DBS)
• Other tVNS companies (e.g., cerbomed, now part of医疗器械)

Recent Developments

Key developments for electroCore include:

• Continued commercial execution in cluster headache
• Expansion of clinical pipeline in neurological conditions
• Publication of PD clinical data
• Ongoing regulatory activities for additional indications

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)](/proteins/parkin)
• [Vagus Nerve Stimulation](/therapeutics/vagus-nerve-stimulation)](/therapeutics)
• [Vagus Nerve Stimulation for Parkinson's Disease](/therapeutics/vagus-nerve-stimulation-parkinsons-disease)](/therapeutics)
• [Transcutaneous VNS for PD Gait](/therapeutics/transcutaneous-vns-parkinson-gait)](/therapeutics)
• [Neuromodulation](/therapeutics/neuromodulation)

External Links

• [electroCore Website](https://www.electrocore.com)](/companies/electrocore)
• [gammaCore Website](https://www.gammacore.com)
• [NASDAQ: ECOR](https://www.nasdaq.com/market-activity/stocks/ecor)

References